Patent ID: 11857585
Assignee: BIONOXX INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  Y | IPC A  C

Claim 12:
13. A method for preparing a recombinant oncolytic virus which expresses a truncated fragment of HSV1-TK (herpes simplex virus thymidine kinase) or a variant thereof according to claim 1, comprising the steps of:
i) transfecting a shuttle plasmid comprising a nucleotide sequence encoding the truncated fragment of HSV1-TK or a variant thereof into a host cell, and treating the host cell with a wild type vaccinia oncolytic virus;
ii) culturing the resulting host cell; and
iii) obtaining the recombinant oncolytic virus from the resulting culture,
wherein the oncolytic virus is a vaccinia virus,
wherein the HSV1-TK comprises the amino acid sequence of SEQ ID NO: 1 and the truncated fragment of HSV1-TK is any one of fragments in which 1 to 195 amino acid residues are consecutively deleted from C-terminus of SEQ ID NO: 1, and
wherein the variant comprises the amino acid sequence of SEQ ID NO: 7 or 8.